Aliskiren Hemifumarate Patent Expiration
Aliskiren Hemifumarate is Used for treating high blood pressure. It was first introduced by Noden Pharma Dac
Aliskiren Hemifumarate Patents
Given below is the list of patents protecting Aliskiren Hemifumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tekturna |
US8617595 (Pediatric) | Galenic formulations of organic compounds | Aug 19, 2026 | Noden Pharma |
| Tekturna | US8617595 | Galenic formulations of organic compounds | Feb 19, 2026 | Noden Pharma |
| Tekturna |
US5559111 (Pediatric) | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jan 21, 2019
(Expired) | Noden Pharma |
| Tekturna | US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul 21, 2018
(Expired) | Noden Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate's patents.
Latest Legal Activities on Aliskiren Hemifumarate's Patents
Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jun, 2021 | US8617595 |
| Post Issue Communication - Certificate of Correction | 23 Mar, 2015 | US8617595 |
| Email Notification Critical | 21 Jan, 2015 | US8617595 |
| Mail-Petition Decision - Dismissed Critical | 13 Jan, 2015 | US8617595 |
| Petition Decision - Dismissed Critical | 12 Jan, 2015 | US8617595 |
| Adjustment of PTA Calculation by PTO | 05 Jan, 2015 | US8617595 |
| Petition Entered | 23 Jan, 2014 | US8617595 |
| Recordation of Patent Grant Mailed Critical | 31 Dec, 2013 | US8617595 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Dec, 2013 | US8617595 |
| Email Notification Critical | 12 Dec, 2013 | US8617595 |
Aliskiren Hemifumarate's Family Patents
Explore Our Curated Drug Screens
Aliskiren Hemifumarate Generic API Manufacturers
Several generic applications have been filed for Aliskiren Hemifumarate.
Given below is the list of companies who have filed for Aliskiren Hemifumarate generic, along with the locations of their manufacturing plants worldwide.
1. ENDO OPERATIONS
Endo Operations Ltd has filed for 2 different strengths of generic version for Aliskiren Hemifumarate. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 150MG BASE | tablet | Prescription | ORAL | AB | Mar 22, 2019 |
| EQ 300MG BASE | tablet | Prescription | ORAL | AB | Mar 22, 2019 |